BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to Merck & Co Inc. (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) topline data from individualized cancer therapy for advanced skin cancer.
At a pre-planned interim analysis, the investigational combination delivered statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to standard Keytruda alone.
BioNTech’s Individualized mRNA Cancer Therapy
Investors should note that BioNTech is developing Autogene cevumeran (BNT122/RO7198457), an individualized mRNA cancer immunotherapy candidate encoding patient-specific tumor neoantigens aiming to induce an immune response against the patient’s individual tumor.
The mechanism of action is similar to Merck/Moderna’s melanoma therapy.
